Subcision Followed by Diluted Calcium Hydroxylapatite Injection Versus Subcision Followed by Painting CROSS TCA Technique for the Treatment of Atrophic Acne Scars
NCT ID: NCT07028567
Last Updated: 2025-06-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
13 participants
INTERVENTIONAL
2023-01-01
2023-06-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Autologous Plasma Gel Injection Versus Polydioxanone Cog Threads Insertion for the Treatment of Atrophic Post-acne Scars: a Split-face
NCT06580691
Nano Fat Injection With or Without Fractional Carbon Dioxide Laser in Acne Scars
NCT05985265
Microneedling With Topical Preparations in the Treatment of Atrophic Post-acne Scars
NCT05600075
Treatment of Acne Scarring With a Novel Procedure Combination
NCT00510055
Carboxytherapy in the Treatment of Atrophic Scars
NCT05695807
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The original chemical reconstruction of skin scars (CROSS) technique using trichloroacetic acid (TCA) entails focal application of highly concentrated TCA (70% to 100%) with firm pressure applied to the entire atrophic area using a sharpened wooden applicator until frosting occurs.
Fillers containing hyaluronic acid, calcium hydroxyapatite, and poly-L-lactic acid are increasingly used to correct atrophic acne scarring as they augment soft tissue in variable degree and are most effective in soft rolling or boxcar scars.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
Patients with atrophic acne scars.
Calcium hydroxylapatite filler
Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
Painting chemical reconstruction of skin scars trichloroacetic acid technique
Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Calcium hydroxylapatite filler
Patients received calcium hydroxylapatite filler (CaHA) (Radiesse®).
Painting chemical reconstruction of skin scars trichloroacetic acid technique
Patients received painting chemical reconstruction of skin scars (CROSS) trichloroacetic acid (TCA) technique.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients with atrophic acne scars.
Exclusion Criteria
* Receiving systemic isotretinoin medication at the time of the study.
* Active bacterial, viral or fungal infections in the treatment area.
* Hypertrophic scarring or keloidal tendency.
* Photosensitivity or photodermatitis.
* Unrealistic expectation, bleeding, coagulation disorders, and any other related skin disease.
* Pregnant or lactating females.
* Chronic debilitating diseases such as diabetes mellitus, cardiovascular diseases, renal failure, hepatic diseases, chronic respiratory diseases or any endocrine diseases.
* History of immunosuppressive drug intake or chemotherapy within 6 months before treatment.
20 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Riham Mohamed ElSayed ElSetiha
Resident of Dermatology and Venereology, Faculty of Medicine, Tanta University, Tanta, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
36195/12/22
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.